Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses

BACKGROUND: In the absence of head-to-head trials comparing axitinib with cabozantinib or everolimus, the aim of this study was to conduct an indirect comparison of their relative efficacy in patients with metastatic renal cell carcinoma (mRCC), using data from the AXIS and METEOR trials. METHODS: P...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Proskorovsky, Irina, Benedict, Agnes, Negrier, Sylvie, Bargo, Danielle, Sandin, Rickard, Ramaswamy, Krishnan, Desai, Jigar, Cappelleri, Joseph C., Larkin, James
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6300002/
https://ncbi.nlm.nih.gov/pubmed/30567533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-5157-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars